Curaleaf
Curaleaf Holdings, Inc. CURA CURLF will report financial and operating results for the third quarter ended September 30, 2024, after the market closes on November 6, 2024.
The cannabis giant announced it will host a conference call and audio webcast at 5pm ET that same day.
Curaleaf reported its second quarter financials in August, revealing revenue of $342 million, a 2% increase from the same period last year. The company also reported a net loss of $48.9 million, or a loss per share of $0.06, for the quarter.
Nevertheless, the company continues to aggressively expand its global and domestic footprint. Internationally, revenue increased 78% in the second quarter, driven by strong results in the UK and Germany.
The company also recognizes the potential of Poland's medical cannabis market, as its subsidiary Curaleaf International expanded into the European country this year through the acquisition of pharmaceutical wholesaler Can4Med, which specializes in cannabinoid medicines. .
Related article: Europe is turning cash flow positive, 'let's see what happens in the US' says Curaleaf's Boris Jordan
Get Benzinga's exclusive analysis and top cannabis industry and market news delivered to your inbox every day, free of charge. Subscribe to our newsletter here. If you're serious about your business, you can't afford to miss it.
Curaleaf appointed executive chairman Boris Jordan as its new CEO in August, after Matt Darling announced plans to retire.
Jordan will be one of the keynote speakers at Benzinga's event in Illinois. Join us for the 19th Annual Benzinga Cannabis Capital Conference in Chicago, October 8-9 of this year. Click this link to get your tickets now before prices go up.
Curaleaf stock is trading 0.67% lower at $2.96 per share as of press time Monday morning.
marimed
MariMed Inc. MRMD MRMD plans to report third quarter financial results after market close on November 6, 2024. Management is scheduled to host a conference call the next day at 8 a.m. ET.
The multi-state cannabis operator disclosed financial results in August for the second quarter ended June 30, 2024, showing revenue of $40.4 million compared to $36.5 million in the year-ago period. It became clear.
John Levine, one of a number of experts and entrepreneurs scheduled to speak at the Benzinga Cannabis Conference in Chicago this week, said MariMed's management is committed to “profit margin expansion and long-term cash flow.” I am confident that we can achieve this increase.” New assets maximize return potential. ”
During the second quarter, the company completed the acquisition of its fifth dispensary, Allgreens Dispensary, located in Illinois.
As of press time on Monday, MariMed stock was trading down 4.40% at $0.152 per share.
Read next:
Market news and data powered by Benzinga API
© 2024 Benzinga.com. Benzinga does not provide investment advice. Unauthorized reproduction is prohibited.
